StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a report published on Sunday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Lipocine Price Performance
LPCN stock traded up $0.24 during midday trading on Friday, hitting $4.92. The company’s stock had a trading volume of 25,727 shares, compared to its average volume of 58,053. Lipocine has a twelve month low of $2.31 and a twelve month high of $7.15. The company’s fifty day moving average price is $4.65 and its 200 day moving average price is $3.63. The stock has a market capitalization of $26.32 million, a P/E ratio of -1.64 and a beta of 1.11.
Lipocine (NASDAQ:LPCN – Get Free Report) last issued its quarterly earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.11. The business had revenue of $0.22 million during the quarter. Equities analysts expect that Lipocine will post -1.49 EPS for the current fiscal year.
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
See Also
- Five stocks we like better than Lipocine
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- Learn Technical Analysis Skills to Master the Stock Market
- 3 Value Stocks You Can Buy Before They Become Big
- How to Use the MarketBeat Excel Dividend Calculator
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
